PD-L1 expression in head and neck cancer tissue specimens decreases with time

Article Medicine, General & Internal

Concordance between Three PD-L1 Immunohistochemical Assays in Head and Neck Squamous Cell Carcinoma (HNSCC) in a Multicenter Study

Elena Guerini Rocco et al.

Summary: This study demonstrates the interchangeability of two antibodies and different immunohistochemical platforms in selecting patients with HNSCC for immunotherapy.

DIAGNOSTICS (2022)

Add to Collection

Article Cell Biology

Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study

Bruna Cerbelli et al.

Summary: The study compared the expression of PD-L1 using CPS and two widely used assays in HNSCC, showing high agreement between the 22C3 PharmDx assay and SP263 assay. This suggests that these assays are interchangeable in selecting patients with HNSCC for immunotherapy.

HISTOPATHOLOGY (2022)

Add to Collection

Article Pathology

PD-L1 expression in head and neck carcinoma by combined positive score: a comparison among preoperative biopsy, tumor resection, and lymph node metastasis

Andrea Ambrosini-Spaltro et al.

Summary: This study compared PD-L1 CPS values in resections of primary tumors, metastatic lymph nodes, and biopsies of primary tumors, showing a high concordance in these samples.

VIRCHOWS ARCHIV (2022)

Add to Collection

Article Oncology

Prognostic role of immune microenvironment in pleural metastases from breast and lung adenocarcinomas

Georgia Karpathiou et al.

Summary: This study investigated the immune microenvironment in patients with lung and breast adenocarcinoma with pleural metastasis. Different immune cell populations were found to be present in the metastatic tissue, and some cell populations were associated with prognosis.

ANNALS OF TRANSLATIONAL MEDICINE (2022)

Add to Collection

Article Pathology

Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)

Emma J. de Ruiter et al.

Summary: This study compared the performance of two PD-L1 standardized assays and one laboratory-developed test in head and neck squamous cell carcinoma, revealing moderate concordance between different staining assays and considerable differences in PD-L1 positivity when using clinically relevant cutoffs. These findings suggest caution is needed when using PD-L1 expression to guide clinical practice.

MODERN PATHOLOGY (2021)

Add to Collection

Article Oncology

Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity

Andy Karabajakian et al.

Summary: The study found temporal heterogeneity of PD-L1 status and TLS/IFN-gamma gene expression surrogates in HNSCC that should be taken into consideration when interpreting biomarker studies.

ORAL ONCOLOGY (2021)

Add to Collection

Article Oncology

The Immune Microenvironment of Chordomas: An Immunohistochemical Analysis

Maroa Dridi et al.

Summary: Chordoma patients may benefit from immunotherapy, as their unique immune microenvironment shows PD-L1+ immune cells playing a negative prognostic role. Higher CD8, presence of PD-L1+ immune cells, and higher vascular density are adverse prognostic factors, with only PD-L1+ immune cells retaining prognostic significance in multivariate analysis. Further studies in this field and the potential beneficial role of immunotherapy in chordoma patients are warranted.

CANCERS (2021)

Add to Collection

Article Oncology